PT-141 (Bremelanotide): The Complete Guide

PT-141, known by its pharmaceutical name bremelanotide, is a synthetic peptide that acts on the central nervous system through the melanocortin receptor pathway to influence sexual desire. It holds a distinction that most peptides discussed in clinical practice do not: bremelanotide received FDA approval in June 2019 under the brand name VYLEESI, specifically for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. This makes it the only FDA-approved melanocortin receptor agonist in clinical use and one of the very few peptide-based treatments to have completed the full Phase 3 trial process. For an overview of how peptide-based therapies work at a biological level, the Complete Beginner’s Guide to Peptide Therapy provides useful foundational context.

What Is PT-141 (Bremelanotide) and How Does It Differ from Other Sexual Health Treatments?

Most medications used for sexual dysfunction work through the vascular system. Phosphodiesterase-5 inhibitors such as sildenafil (Viagra) increase blood flow to genital tissue; they work peripherally and require physical arousal to produce their effect. Bremelanotide works through an entirely different pathway. It is a central nervous system agent, meaning it crosses into the brain and acts on melanocortin receptors in neural circuits involved in sexual motivation and arousal rather than on blood vessels or genital tissue directly.

This distinction is clinically important for two reasons. First, it means bremelanotide addresses desire itself rather than the physical mechanics of sexual response, which is why it was studied and approved specifically for HSDD, a condition defined by absent or significantly reduced sexual desire that causes personal distress. Second, it means the mechanism of action is more complex and less well understood than vascular agents, which has implications for both its therapeutic profile and its side effect pattern.

The Melanocortin System: How PT-141 Bremelanotide Works

The melanocortin system is a network of receptors distributed throughout the brain and body that regulates a wide range of physiological functions, including energy balance, inflammation, pigmentation, and sexual behavior. The relevant receptors for bremelanotide’s effects on sexual function are MC3R and MC4R, which are concentrated in hypothalamic and limbic brain regions involved in sexual motivation.

Bremelanotide is a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH), a naturally occurring melanocortin. When administered subcutaneously, it reaches systemic circulation and crosses the blood-brain barrier, where it binds to and activates MC3R and MC4R receptors. The downstream effects of this receptor activation in neural circuits associated with sexual arousal are believed to underlie its observed effects on sexual desire, though the precise cellular and circuit-level mechanisms remain an active area of investigation.

The melanocortin system also includes MC1R, which regulates skin pigmentation, and MC2R, which is involved in cortisol production. Bremelanotide has lower affinity for these receptors at therapeutic doses, but the residual activity at MC1R is responsible for one of its notable potential long-term side effects, discussed below under safety considerations.

Melanocortin pathway vs. vascular pathways in sexual health

FDA Approval: What VYLEESI Is Approved For and What It Is Not

The FDA approval of bremelanotide under the name VYLEESI covers one specific indication: treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. This is not a general approval for sexual enhancement or any other use. The approval was supported by two Phase 3 randomized, double-blind, placebo-controlled trials, RECONNECT 1 and RECONNECT 2, which enrolled a combined 1,247 premenopausal women with a diagnosis of HSDD.

In the RECONNECT trials, women using bremelanotide reported statistically significant improvements in satisfying sexual events and desire scores compared to placebo at 24 weeks. The effect sizes were modest in absolute terms, and the FDA label notes that not all women will respond. The approval explicitly excludes use in women whose low sexual desire is explained by relationship problems, a co-occurring medical or psychiatric condition, a medication side effect, or other identifiable causes not consistent with the HSDD diagnosis criteria.

VYLEESI is not approved for use in men, in postmenopausal women, or as a general sexual performance enhancer in any population. These are off-label contexts. Off-label prescribing by licensed physicians is legal and common, but the evidence base for those uses is different in character from the FDA-approved indication, as discussed below.

PT-141 in Men: What the Research Shows

Bremelanotide was originally investigated as a potential treatment for erectile dysfunction in men before the research focus shifted toward HSDD. Multiple Phase 1 and Phase 2 studies evaluated PT-141 in men with erectile dysfunction, including men who had not responded adequately to sildenafil. Published results from these earlier studies demonstrated increases in penile erection scores and patient-reported sexual satisfaction compared to placebo. The studies were conducted using intranasal delivery (a formulation that was subsequently discontinued due to concerns about transient blood pressure elevation) and later subcutaneous injection.

These studies did not proceed to Phase 3 in men, and bremelanotide has not been submitted for or received FDA approval for any indication in men. The available evidence in men consists of earlier-phase data that is consistent with a biological effect but does not constitute the same level of evidence as the completed Phase 3 trials conducted in women. When bremelanotide is discussed in the context of men’s sexual health, it is in the category of off-label use with Phase 2 level supporting evidence. The distinction between FDA-approved and studied-off-label should be clear to any patient considering either option.

For context on how hormonal and peptide-based therapies interact with men’s sexual and metabolic health, the article on Testosterone and Body Composition After 40 covers the androgenic picture that often overlaps with discussions of sexual function.

Who May Discuss PT-141 With a Provider

Bremelanotide is a prescription medication. In its FDA-approved indication, it is prescribed by licensed providers to premenopausal women who have received a formal diagnosis of HSDD, defined as low sexual desire that causes marked personal distress and is not better explained by another condition or medication. The diagnosis requires a clinical evaluation that rules out contributing factors such as depression, anxiety, hormonal conditions, relationship factors, and medications known to reduce sexual desire (including many antidepressants and oral contraceptives).

For premenopausal women with confirmed HSDD, bremelanotide represents a treatment option with FDA-level evidence backing its approval. For postmenopausal women, for men, or for individuals whose desire concerns arise in a different context, bremelanotide may still be discussed with a provider as part of an individualized evaluation, but that falls outside its approved indication. A thorough evaluation includes reviewing contributing conditions and ruling out causes that might be more directly addressable before considering bremelanotide as part of a treatment plan.

Understanding the Side Effect Profile of PT-141 Bremelanotide

The side effect profile of bremelanotide is one of the most clinically significant aspects of any discussion with patients considering it. In the RECONNECT Phase 3 trials, the following adverse effects were documented at rates that distinguish it from placebo:

Protocol and Administration: What a Bremelanotide Regimen Looks Like

The FDA-approved administration of bremelanotide is as a subcutaneous injection administered approximately 45 minutes before anticipated sexual activity. The prescribing information specifies using no more than one dose in a 24-hour period and limiting use to no more than approximately 8 doses per month, primarily because of the risk of focal hyperpigmentation with more frequent administration. The injection is self-administered using a single-dose autoinjector into the abdomen or thigh.

The on-demand nature of bremelanotide distinguishes it from daily-use medications. It is not a chronic daily therapy but rather a situational treatment. This has implications both for patient selection (it suits patients who want an as-needed option rather than a daily regimen) and for monitoring (responses per occasion are more variable than steady-state effects from daily medications).

Compounded versions of bremelanotide are also available through licensed 503A compounding pharmacies with a valid prescription, distinct from the FDA-approved VYLEESI product. Compounded preparations are regulated differently from branded pharmaceutical products and are prepared for individual patients. A provider evaluating bremelanotide as part of a patient’s plan will discuss whether the FDA-approved product or a compounded formulation is most appropriate based on individual circumstances and current availability. The Lab Checklist Before Starting Peptide Therapy covers the baseline assessments that precede any new peptide or hormone protocol.

What a First Consultation About Bremelanotide Covers

A clinical evaluation for bremelanotide begins with a comprehensive history that assesses the nature and duration of low sexual desire, the degree of personal distress it causes, contributing medical and psychiatric conditions, current medications (particularly antidepressants, antipsychotics, and hormonal contraceptives, all of which can reduce sexual desire), relationship and psychosocial factors, and relevant hormone levels. This evaluation is important because HSDD is a diagnosis of exclusion: the low desire must be primary rather than secondary to another identifiable and treatable cause.

Relevant laboratory assessments typically include thyroid function (hypothyroidism commonly reduces libido), sex hormone panel (testosterone, estradiol, SHBG), and in some cases prolactin (elevated prolactin from any cause is a known driver of reduced desire). A full hormone panel provides the context needed to determine whether bremelanotide alone addresses the clinical picture or whether a broader protocol is more appropriate. For an overview of what to expect in a first evaluation, the First Peptide Therapy Consultation guide covers the process in detail.

Sexual health concerns often exist alongside broader hormonal and metabolic health patterns. The Peptides and Healthy Aging article provides context on how different peptide-based options fit within a broader health optimization approach for adults over 40.